Skip to search formSkip to main contentSkip to account menu

Saphris

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
OBJECTIVE To assess clinical features of therapeutic efficacy and tolerability of asenapine (saphris) in stopping acute psychotic… 
Review
2015
Review
2015
The causes and origins of pica remain unknown and are the source of speculation and heated debate. Bariatric surgery patients are… 
Review
2015
Review
2015
Asenapine (Saphris®) is an atypical antipsychotic drug which has been approved by the US Food and Drug Administration for the… 
Review
2011
Review
2011
Asenapine was approved by the Food and Drug Administration (FDA) in 2009. This article reviews clinically significant aspects of… 
2011
2011
T he US health system is under reform. More than ever, busy practitioners need help in prescribing drugs more knowledgeably and… 
Review
2011
Review
2011
Antipsychotic drugs are commonly prescribed for a variety of psychiatric conditions. In addition to individuals with… 
Review
2011
Review
2011
  • R. McIntyre
  • CNS Neuroscience & Therapeutics
  • 2011
  • Corpus ID: 39431317
The second generation atypical antipsychotic, asenapine (Saphris), was approved by the US FDA (August 2009) for the acute… 
2010
2010
  • C. Hopkins
  • ACS Chemical Neuroscience
  • 2010
  • Corpus ID: 37151022
On August 14th, 2009, for the first time, the FDA has approved a psychotropic medication for two indications simultaneously… 
2010
2010
  • JAAPA : official journal of the American Academy…
  • 2010
  • Corpus ID: 11751591
2010
2010
Antipsychotic agents Asenapine (Saphris—Schering) and iloperidone (Fanapt—Vanda) are new atypical antipsychotic agents that join…